{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:15:36Z","timestamp":1790813736834,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T00:00:00Z","timestamp":1694217600000},"content-version":"vor","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI145781"],"award-info":[{"award-number":["R01AI145781"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI165721"],"award-info":[{"award-number":["R01AI165721"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.medj.2022.07.001","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T10:32:23Z","timestamp":1661769143000},"page":"603-611.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Interleukin-1 receptor antagonist anakinra as treatment for paradoxical responses in HIV-negative tuberculosis patients: A case series"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0995-018X","authenticated-orcid":false,"given":"Cynthia","family":"van Arkel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Boeree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Magis-Escurra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Hoefsloot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeltje","family":"Carpaij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakko","family":"van Ingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoert","family":"Pegge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Wielders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Smeenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Aarnoutse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai G.","family":"Netea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinout","family":"van Crevel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan","family":"van Laarhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2022.07.001_bib1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s15010-012-0376-9","article-title":"Paradoxical reactions during treatment of tuberculosis with extrapulmonary manifestations in HIV-negative patients","volume":"41","author":"Geri","year":"2013","journal-title":"Infection"},{"key":"10.1016\/j.medj.2022.07.001_bib2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s10096-002-0821-2","article-title":"Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients","volume":"21","author":"Cheng","year":"2002","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.medj.2022.07.001_bib3","first-page":"677","article-title":"Inflammasome activation underlying central nervous system deterioration in HIV-associated tuberculosis","volume":"215","author":"Marais","year":"2017","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.medj.2022.07.001_bib4","doi-asserted-by":"crossref","first-page":"8451","DOI":"10.1038\/ncomms9451","article-title":"HIV-tuberculosis-associated immune reconstitution inflammatory syndrome is characterized by Toll-like receptor and inflammasome signalling","volume":"6","author":"Lai","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2022.07.001_bib5","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/acn3.656","article-title":"Cerebral autoinflammatory disease treated with anakinra","volume":"5","author":"Jang","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.medj.2022.07.001_bib6","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2665-9913(20)30096-5","article-title":"Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. The Lancet","volume":"2","author":"Mehta","year":"2020","journal-title":"Lancet. Rheumatol."},{"key":"10.1016\/j.medj.2022.07.001_bib7","doi-asserted-by":"crossref","first-page":"e84585","DOI":"10.1371\/journal.pone.0084585","article-title":"Incidence of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome and impact on patient outcome","volume":"8","author":"Bonnet","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.medj.2022.07.001_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0163-4453(98)92838-9","article-title":"Central nervous system tuberculosis--the paradox of the host immune response","volume":"36","author":"Marshall","year":"1998","journal-title":"J.\u00a0Infect."},{"key":"10.1016\/j.medj.2022.07.001_bib9","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1086\/517479","article-title":"Selective increase in plasma tumor necrosis factor-alpha and concomitant clinical deterioration after initiating therapy in patients with severe tuberculosis","volume":"178","author":"Bekker","year":"1998","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.medj.2022.07.001_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijid.2014.12.030","article-title":"Paradoxical reactions and immune reconstitution inflammatory syndrome in tuberculosis","volume":"32","author":"Bell","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.medj.2022.07.001_bib11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jinf.2006.01.002","article-title":"Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy","volume":"53","author":"Manosuthi","year":"2006","journal-title":"J.\u00a0Infect."},{"key":"10.1016\/j.medj.2022.07.001_bib12","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fphar.2018.01157","article-title":"Anakinra therapy for non-cancer inflammatory diseases","volume":"9","author":"Cavalli","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.medj.2022.07.001_bib13","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1086\/592695","article-title":"Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes","volume":"47","author":"Blackmore","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medj.2022.07.001_bib14","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10141","article-title":"Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial","volume":"46","author":"Cohen","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.medj.2022.07.001_bib15","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1177\/0956462420915394","article-title":"Anakinra in the treatment of protracted paradoxical inflammatory reactions in HIV-associated tuberculosis in the United Kingdom: a report of two cases","volume":"31","author":"Keeley","year":"2020","journal-title":"Int. J. STD AIDS"},{"key":"10.1016\/j.medj.2022.07.001_bib16","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1093\/cid\/ciaa1826","article-title":"Thalidomide use for complicated central nervous system tuberculosis in children: insights from an observational cohort","volume":"72","author":"van Toorn","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medj.2022.07.001_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann. Rheum. Dis."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634022003117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634022003117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:55:43Z","timestamp":1763002543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634022003117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2666634022003117"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2022.07.001","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-1 receptor antagonist anakinra as treatment for paradoxical responses in HIV-negative tuberculosis patients: A case series","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2022.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}